VXRT

Vaxart, Inc. (NASDAQ:VXRT) is a clinical-stage biotechnology company founded in 1981 and headquartered in South San Francisco, California. The company specializes in developing oral recombinant protein vaccines using its proprietary oral vaccine platform technology. Unlike traditional injectable vaccines, Vaxart's approach focuses on delivering vaccines in pill form to stimulate mucosal immunity, which the company believes may provide superior protection against infectious diseases. The company has evolved from early-stage research to conducting multiple Phase II clinical trials, with significant government backing including a major contract from the Biomedical Advanced Research and Development Authority (BARDA).